P548: BEMCENTINIB COMBINED WITH LOW-DOSE CYTARABINE IS EFFICACIOUS AND WELL TOLERATED IN RELAPSED AML PATIENTS UNFIT FOR INTENSIVE CHEMOTHERAPY. UPDATES FROM THE ONGOING PHASE II TRIAL (NCT02488408)
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000845080.27665.da |
| _version_ | 1797285855877922816 |
|---|---|
| author | S. Loges M. Heuser J. Chromik G. Sutamtewagul S. Kapp-Schwoerer M. Crugnola N. Di Renzo R. Lemoli D. Mattei I. Ben-Batalla J. Waizenegger L.-M. Rieckmann M. Janning C. D. Imbusch N. Beumer D. Micklem C. Gorcea-Carson G. Lawson J. Nautiyal S. Deharo W. Fiedler Y. Alvarado-Valero B. Gjertsen |
| author_facet | S. Loges M. Heuser J. Chromik G. Sutamtewagul S. Kapp-Schwoerer M. Crugnola N. Di Renzo R. Lemoli D. Mattei I. Ben-Batalla J. Waizenegger L.-M. Rieckmann M. Janning C. D. Imbusch N. Beumer D. Micklem C. Gorcea-Carson G. Lawson J. Nautiyal S. Deharo W. Fiedler Y. Alvarado-Valero B. Gjertsen |
| author_sort | S. Loges |
| collection | DOAJ |
| first_indexed | 2024-03-07T18:09:26Z |
| format | Article |
| id | doaj.art-3441cbe6330b4ee4853cf278fc6307e5 |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T18:09:26Z |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-3441cbe6330b4ee4853cf278fc6307e52024-03-02T07:47:35ZengWileyHemaSphere2572-92412022-06-01644744810.1097/01.HS9.0000845080.27665.da202206003-00447P548: BEMCENTINIB COMBINED WITH LOW-DOSE CYTARABINE IS EFFICACIOUS AND WELL TOLERATED IN RELAPSED AML PATIENTS UNFIT FOR INTENSIVE CHEMOTHERAPY. UPDATES FROM THE ONGOING PHASE II TRIAL (NCT02488408)S. Loges0M. Heuser1J. Chromik2G. Sutamtewagul3S. Kapp-Schwoerer4M. Crugnola5N. Di Renzo6R. Lemoli7D. Mattei8I. Ben-Batalla9J. Waizenegger10L.-M. Rieckmann11M. Janning12C. D. Imbusch13N. Beumer14D. Micklem15C. Gorcea-Carson16G. Lawson17J. Nautiyal18S. Deharo19W. Fiedler20Y. Alvarado-Valero21B. Gjertsen221 DKFZ-Hector Cancer Institute, University Medical Center Mannheim, Mannheim4 Hematology, Haemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover5 University Hospital Frankfurt, Frankfurt, Germany6 University of Iowa Hospitals and Clinics, Iowa City, United States of America7 University Hospital of Ulm, Ulm, Germany8 University of Parma, Parma9 Haematology and SCT Unit, Vito Fazzi Hospital, Lecce10 University of Genoa, Genoa11 ASOS. Croce e Carle, Cuneo, Italy1 DKFZ-Hector Cancer Institute, University Medical Center Mannheim, Mannheim1 DKFZ-Hector Cancer Institute, University Medical Center Mannheim, Mannheim1 DKFZ-Hector Cancer Institute, University Medical Center Mannheim, Mannheim1 DKFZ-Hector Cancer Institute, University Medical Center Mannheim, Mannheim2 Division of Personalized Medical Oncology (A420), German Cancer Research Center (DKFZ), Heidelberg1 DKFZ-Hector Cancer Institute, University Medical Center Mannheim, Mannheim13 BerGenBio ASA, Bergen, Norway14 BerGenBio Ltd, Oxford, United Kingdom14 BerGenBio Ltd, Oxford, United Kingdom14 BerGenBio Ltd, Oxford, United Kingdom14 BerGenBio Ltd, Oxford, United Kingdom15 University Medical Center Hamburg, Hamburg, Germany16 The University of Texas M.D. Anderson Cancer Center, Houston, United States of America17 Haukeland University Hospital, Bergen, Norwayhttp://journals.lww.com/10.1097/01.HS9.0000845080.27665.da |
| spellingShingle | S. Loges M. Heuser J. Chromik G. Sutamtewagul S. Kapp-Schwoerer M. Crugnola N. Di Renzo R. Lemoli D. Mattei I. Ben-Batalla J. Waizenegger L.-M. Rieckmann M. Janning C. D. Imbusch N. Beumer D. Micklem C. Gorcea-Carson G. Lawson J. Nautiyal S. Deharo W. Fiedler Y. Alvarado-Valero B. Gjertsen P548: BEMCENTINIB COMBINED WITH LOW-DOSE CYTARABINE IS EFFICACIOUS AND WELL TOLERATED IN RELAPSED AML PATIENTS UNFIT FOR INTENSIVE CHEMOTHERAPY. UPDATES FROM THE ONGOING PHASE II TRIAL (NCT02488408) HemaSphere |
| title | P548: BEMCENTINIB COMBINED WITH LOW-DOSE CYTARABINE IS EFFICACIOUS AND WELL TOLERATED IN RELAPSED AML PATIENTS UNFIT FOR INTENSIVE CHEMOTHERAPY. UPDATES FROM THE ONGOING PHASE II TRIAL (NCT02488408) |
| title_full | P548: BEMCENTINIB COMBINED WITH LOW-DOSE CYTARABINE IS EFFICACIOUS AND WELL TOLERATED IN RELAPSED AML PATIENTS UNFIT FOR INTENSIVE CHEMOTHERAPY. UPDATES FROM THE ONGOING PHASE II TRIAL (NCT02488408) |
| title_fullStr | P548: BEMCENTINIB COMBINED WITH LOW-DOSE CYTARABINE IS EFFICACIOUS AND WELL TOLERATED IN RELAPSED AML PATIENTS UNFIT FOR INTENSIVE CHEMOTHERAPY. UPDATES FROM THE ONGOING PHASE II TRIAL (NCT02488408) |
| title_full_unstemmed | P548: BEMCENTINIB COMBINED WITH LOW-DOSE CYTARABINE IS EFFICACIOUS AND WELL TOLERATED IN RELAPSED AML PATIENTS UNFIT FOR INTENSIVE CHEMOTHERAPY. UPDATES FROM THE ONGOING PHASE II TRIAL (NCT02488408) |
| title_short | P548: BEMCENTINIB COMBINED WITH LOW-DOSE CYTARABINE IS EFFICACIOUS AND WELL TOLERATED IN RELAPSED AML PATIENTS UNFIT FOR INTENSIVE CHEMOTHERAPY. UPDATES FROM THE ONGOING PHASE II TRIAL (NCT02488408) |
| title_sort | p548 bemcentinib combined with low dose cytarabine is efficacious and well tolerated in relapsed aml patients unfit for intensive chemotherapy updates from the ongoing phase ii trial nct02488408 |
| url | http://journals.lww.com/10.1097/01.HS9.0000845080.27665.da |
| work_keys_str_mv | AT sloges p548bemcentinibcombinedwithlowdosecytarabineisefficaciousandwelltoleratedinrelapsedamlpatientsunfitforintensivechemotherapyupdatesfromtheongoingphaseiitrialnct02488408 AT mheuser p548bemcentinibcombinedwithlowdosecytarabineisefficaciousandwelltoleratedinrelapsedamlpatientsunfitforintensivechemotherapyupdatesfromtheongoingphaseiitrialnct02488408 AT jchromik p548bemcentinibcombinedwithlowdosecytarabineisefficaciousandwelltoleratedinrelapsedamlpatientsunfitforintensivechemotherapyupdatesfromtheongoingphaseiitrialnct02488408 AT gsutamtewagul p548bemcentinibcombinedwithlowdosecytarabineisefficaciousandwelltoleratedinrelapsedamlpatientsunfitforintensivechemotherapyupdatesfromtheongoingphaseiitrialnct02488408 AT skappschwoerer p548bemcentinibcombinedwithlowdosecytarabineisefficaciousandwelltoleratedinrelapsedamlpatientsunfitforintensivechemotherapyupdatesfromtheongoingphaseiitrialnct02488408 AT mcrugnola p548bemcentinibcombinedwithlowdosecytarabineisefficaciousandwelltoleratedinrelapsedamlpatientsunfitforintensivechemotherapyupdatesfromtheongoingphaseiitrialnct02488408 AT ndirenzo p548bemcentinibcombinedwithlowdosecytarabineisefficaciousandwelltoleratedinrelapsedamlpatientsunfitforintensivechemotherapyupdatesfromtheongoingphaseiitrialnct02488408 AT rlemoli p548bemcentinibcombinedwithlowdosecytarabineisefficaciousandwelltoleratedinrelapsedamlpatientsunfitforintensivechemotherapyupdatesfromtheongoingphaseiitrialnct02488408 AT dmattei p548bemcentinibcombinedwithlowdosecytarabineisefficaciousandwelltoleratedinrelapsedamlpatientsunfitforintensivechemotherapyupdatesfromtheongoingphaseiitrialnct02488408 AT ibenbatalla p548bemcentinibcombinedwithlowdosecytarabineisefficaciousandwelltoleratedinrelapsedamlpatientsunfitforintensivechemotherapyupdatesfromtheongoingphaseiitrialnct02488408 AT jwaizenegger p548bemcentinibcombinedwithlowdosecytarabineisefficaciousandwelltoleratedinrelapsedamlpatientsunfitforintensivechemotherapyupdatesfromtheongoingphaseiitrialnct02488408 AT lmrieckmann p548bemcentinibcombinedwithlowdosecytarabineisefficaciousandwelltoleratedinrelapsedamlpatientsunfitforintensivechemotherapyupdatesfromtheongoingphaseiitrialnct02488408 AT mjanning p548bemcentinibcombinedwithlowdosecytarabineisefficaciousandwelltoleratedinrelapsedamlpatientsunfitforintensivechemotherapyupdatesfromtheongoingphaseiitrialnct02488408 AT cdimbusch p548bemcentinibcombinedwithlowdosecytarabineisefficaciousandwelltoleratedinrelapsedamlpatientsunfitforintensivechemotherapyupdatesfromtheongoingphaseiitrialnct02488408 AT nbeumer p548bemcentinibcombinedwithlowdosecytarabineisefficaciousandwelltoleratedinrelapsedamlpatientsunfitforintensivechemotherapyupdatesfromtheongoingphaseiitrialnct02488408 AT dmicklem p548bemcentinibcombinedwithlowdosecytarabineisefficaciousandwelltoleratedinrelapsedamlpatientsunfitforintensivechemotherapyupdatesfromtheongoingphaseiitrialnct02488408 AT cgorceacarson p548bemcentinibcombinedwithlowdosecytarabineisefficaciousandwelltoleratedinrelapsedamlpatientsunfitforintensivechemotherapyupdatesfromtheongoingphaseiitrialnct02488408 AT glawson p548bemcentinibcombinedwithlowdosecytarabineisefficaciousandwelltoleratedinrelapsedamlpatientsunfitforintensivechemotherapyupdatesfromtheongoingphaseiitrialnct02488408 AT jnautiyal p548bemcentinibcombinedwithlowdosecytarabineisefficaciousandwelltoleratedinrelapsedamlpatientsunfitforintensivechemotherapyupdatesfromtheongoingphaseiitrialnct02488408 AT sdeharo p548bemcentinibcombinedwithlowdosecytarabineisefficaciousandwelltoleratedinrelapsedamlpatientsunfitforintensivechemotherapyupdatesfromtheongoingphaseiitrialnct02488408 AT wfiedler p548bemcentinibcombinedwithlowdosecytarabineisefficaciousandwelltoleratedinrelapsedamlpatientsunfitforintensivechemotherapyupdatesfromtheongoingphaseiitrialnct02488408 AT yalvaradovalero p548bemcentinibcombinedwithlowdosecytarabineisefficaciousandwelltoleratedinrelapsedamlpatientsunfitforintensivechemotherapyupdatesfromtheongoingphaseiitrialnct02488408 AT bgjertsen p548bemcentinibcombinedwithlowdosecytarabineisefficaciousandwelltoleratedinrelapsedamlpatientsunfitforintensivechemotherapyupdatesfromtheongoingphaseiitrialnct02488408 |